<DOC>
	<DOCNO>NCT02362048</DOCNO>
	<brief_summary>ACP-196 Alone Combination Pembrolizumab Subjects Advanced Metastatic Pancreatic Cancer</brief_summary>
	<brief_title>ACP-196 Alone Combination With Pembrolizumab Subjects With Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Men woman ≥ 18 year age ECOG performance status 0 1 Histologically cytologically confirm advanced pancreatic ductal adenocarcinoma unresectable metastatic Prior therapy ≥ 1 systemic chemotherapy regimen unresectable metastatic pancreatic cancer unwilling/unable receive systemic chemotherapy Prior malignancy ( pancreatic cancer ) , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer subject disease free ≥ 2 year limit survival &lt; 2 year . Known central nervous system ( CNS ) metastases and/or carcinomatous meningitis Significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure , myocardial infarction within 6 month screen Malabsorption syndrome , disease significantly affect gastrointestinal function , resection stomach small bowel , symptomatic inflammatory bowel disease , partial complete bowel obstruction Breastfeeding pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>